On June 2, 2024, Moderna Inc. released the first Phase 3 results for its mRNA‑4157 cancer vaccine combined with Merck's Keytruda in a 1,200‑patient melanoma trial. The data showed a 12‑month disease‑free survival (DFS) of 71% versus 66% for Keytruda alone, but no statistically significant improvement in overall survival (OS) at 24 months, and the FDA advisory panel raised concerns about the vaccine's ability to prevent recurrence long‑term.
The modest DFS gain suggests the vaccine may add value only in a narrow therapeutic window, limiting its commercial upside in a market dominated by checkpoint inhibitors. Moreover, the lack of OS benefit raises questions for payers about reimbursement and could dampen investor enthusiasm for Moderna's oncology pipeline.